Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Wednesday's Bonus News Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech SectorReported by Jeffrey Neal Johnson. Date Posted: 2/24/2026. 
Key Takeaways - Johnson & Johnson has maintained an impressive streak of increasing its dividend payouts for generations, rewarding long-term shareholders with reliable income.
- Management is driving future expansion by focusing on high-growth pharmaceutical assets and cutting-edge medical technologies, such as robotics.
- Investors looking for shelter from market volatility benefit from a stock that historically moves much less than the broader market indices.
While the technology sector faces a renewed wave of volatility driven by artificial intelligence (AI) scare trades and valuation concerns, a different story is unfolding in the healthcare sector. Investors fleeing the jittery price swings of high-growth tech stocks are finding shelter in a familiar name that is quietly outperforming. Johnson & Johnson (NYSE: JNJ) is trading near all-time highs of about $245 per share, creating a divergence that has caught Wall Street's attention. This rally undercuts the common perception of the healthcare giant as a slow-moving, "boring" stock. Over the last 30 days, shares have climbed roughly 14%, significantly outperforming the broader market during a period of uncertainty. That price action suggests institutional money is rotating out of riskier assets and placing a premium on stability, reliable cash flow, and consistent execution. For 10,000 years, progress had one bottleneck: the human mind. If you wanted to solve more problems, cure more diseases, or build more wealth, you needed more people, bigger teams, bigger brains, more hours. That unbroken link between human cognition and economic output just shattered. We've crossed what we're calling the Cognitive Decoupling, the moment intelligence was permanently separated from human labor. An AI model just solved a mathematics problem that stumped the world's best minds for decades in 15 minutes, another cracked a 50-year grand challenge in biology that would have taken scientists a century, and McKinsey found that AI can already perform tasks that occupy 44% of U.S. work hours today. This snap is creating a divide: those who own the assets of this new economy will grow wildly wealthy, while those who cling to old-world skills will be left behind. See the stocks to buy, sell, and three money moves now For investors watching the ticker today, Feb. 24, 2026, note one calendar event: today is the ex-dividend date for Johnson & Johnson. The stock will likely open lower by the amount of the upcoming dividend payment—$1.30 per share—a mechanical market adjustment rather than a reflection of underlying business performance. For income-focused investors, this technical dip often represents an attractive entry point rather than a sell signal. 64 Years of Unbroken Growth The primary argument for holding Johnson & Johnson during turbulent market cycles is its financial stability and role as a portfolio stabilizer. The company belongs to an elite group of equities known as Dividend Kings: firms that have increased their dividend payout for at least 50 consecutive years. Johnson & Johnson has now raised its dividend for 64 consecutive years, a track record that spans multiple recessions, market crashes, and geopolitical conflicts. That reliability is a rare commodity in a market still fixated on speculative growth. The stock yields roughly 2.12% based on an annual payout of $5.20 per share. While higher yields can be found in bonds or riskier sectors, the appeal here is the blend of growth and safety. The dividend is backed by a substantial liquidity cushion: management projects free cash flow of about $21 billion in 2026. That level of cash generation helps ensure the company can continue paying shareholders, invest in R&D, and manage legal expenses without heavy borrowing. For risk-averse investors, one of the most compelling metrics is the stock's beta. Beta measures how much a stock moves compared to the overall market (S&P 500), where 1.0 indicates movement in lockstep with the market. Johnson & Johnson's beta is just 0.35, meaning the stock has historically been about 65% less volatile than the broader market. When tech stocks swing wildly, J&J tends to hold its ground. Adding JNJ to a tech-heavy portfolio acts as a mathematical shock absorber, dampening overall volatility while still providing equity exposure. Beyond the Patent Cliff: The Road to $100 Billion A common misconception about safe, dividend-paying stocks is that they cannot grow. Johnson & Johnson is currently disproving that idea with a strategic pivot that appears to be paying off. Management has issued strong guidance for 2026, projecting full-year revenue to surpass $100 billion for the first time in the company's history. Alongside this milestone, the company anticipates adjusted earnings per share (EPS) of about $11.53. This growth is being driven by a reinvigorated pharmaceutical division, now branded as Innovative Medicine. For years, investors worried about the patent cliff after Stelara, a blockbuster immunology drug, lost exclusivity in 2025. Typically, a top drug facing generic competition sees revenue decline sharply. J&J has offset this pressure through the strong performance of newer blockbusters. Two key assets are driving this resilience: - Darzalex: This oncology mainstay generates approximately $14 billion in annual sales and has cemented the company's leadership in treating multiple myeloma.
- Tremfya: Positioned as a successor in the immunology portfolio, Tremfya recently posted strong three-year remission data for ulcerative colitis—helping J&J retain market share as older drugs fade.
The Tech in MedTech: High-Margin Technologies The growth story extends beyond pharmaceuticals into MedTech. That segment has shifted toward high-growth, higher-margin technologies, highlighted by the integration of Shockwave Medical into J&J's cardiovascular portfolio. Shockwave uses intravascular lithotripsy (IVL) technology—sonic pressure waves that safely break up calcified plaque in arteries, similar to the treatment for kidney stones. This is a meaningful upgrade over traditional angioplasty balloons, and it gives J&J a high-growth asset that complements its broader cardiovascular and surgical businesses. The company is also pushing into robotics. The submission of its Ottava robotic surgical system for FDA approval signals an intent to compete directly in the fast-growing soft-tissue robotics market. These devices often carry higher profit margins and create sticky relationships with hospital systems, providing a durable earnings tailwind beyond simple consumables or basic surgical tools. Addition by Subtraction: The Orthopedics Strategy To sustain growth and improve margins, management is actively reshaping the corporate structure. One major development is the potential separation or sale of the DePuy Synthes orthopedics business. Originally planned as a spin-off, recent reports indicate the company is exploring a possible mega sale of the asset. Divesting the orthopedics unit would be a classic example of addition by subtraction. Orthopedics is a mature, lower-growth segment relative to booming fields like oncology and cardiovascular technologies. Shedding this slower unit would improve overall revenue growth and profit margins. A sale would also generate a significant lump-sum payment—potentially billions—providing capital for acquisitions, debt reduction, or share buybacks. Addressing legal risks is essential for any balanced analysis. Johnson & Johnson continues to face litigation over talc products, with a recent $1.5 billion verdict keeping the issue in the headlines. A new commercial lawsuit from Bayer over marketing claims for prostate cancer drugs has also added noise to the news cycle. However, the stock's recent rally suggests investors are looking past these headlines. Many bulls believe J&J has the financial depth to manage such liabilities without disrupting operations. With more than $20 billion in cash and marketable securities, potential proceeds from an orthopedics sale, and roughly $21 billion in annual free cash flow, the company has a financial fortress that can absorb legal settlements—keeping them a line item on the balance sheet rather than an existential threat to the dividend or the business. Capital Preservation With Upside Johnson & Johnson has evolved from a sprawling conglomerate into a more focused, high-tech healthcare company. After spinning off its consumer health division (Kenvue (NYSE: KVUE)) and potentially divesting orthopedics, management is streamlining operations to emphasize high-growth opportunities in pharmaceuticals and medical technology. Although the stock trades near all-time highs and is no longer a deep value play, it offers a compelling mix of capital preservation and upside. The combination of a 64-year dividend-growth streak, a low volatility profile, and a clear path to $100 billion in revenue makes J&J an attractive option for 2026. For investors exhausted by the unpredictability of the technology sector, Johnson & Johnson demonstrates that, in the current market, boring can be both beautiful and profitable.
| 
